L-Fucose therapy could treat GLUT1 deficiency syndrome, study says
Oral L-Fucose Therapy Trial Results in GLUT1 Deficiency Syndrome
Ist dieser Transport gestört, fehlt dem Gehirn ein wichtiger Energielieferant,
erklärt Prof. Dr. Thorsten Marquardt, Leiter der Arbeitsgruppe für angeborene Stoffwechselerkrankungen an der Universität Münster. Following the publication of a study in the Journal of Neurology, researchers reported that oral L-Fucose therapy could serve as a promising additional treatment approach for GLUT1 deficiency syndrome, identifying an unrecognized fucose deficiency in the metabolic disorder. The rare congenital metabolic disorder is characterized by insufficient glucose reaching the brain due to the defect, and the study describes the developmental progress and biochemical changes of a young boy who represents the first patient worldwide ever treated with fucose. Researchers note that previous insufficient treatment results may be attributed to this fucose deficiency. L-fucose is not to be confused with fructose. Previous studies showed that the GLUT1 transport protein transports L-fucose into the brain alongside glucose, providing the starting point for the investigations conducted by the team from the University of Münster and the University Hospital Münster alongside partners from the USA.
Ketogenic Diet Provides Alternative Energy for GLUT1 Disorder
The rare congenital metabolic disorder involves an altered SLC2A1 gene, which provides the blueprint for the GLUT1 transport protein responsible for carrying glucose into the brain. Without sufficient glucose, patients often experience epileptic seizures, movement disorders, and developmental delays. While a ketogenic diet, which is very low in carbohydrate and extremely rich in fat, provides alternative energy sources by supplying alternative energy carriers to the brain, persistent symptoms frequently remain. In the study detailed by the Journal of Neurology, a young male patient diagnosed with a severe form of the condition at two months of age received oral L-Fucose starting at 22 months over an 18-month period.
Initial laboratory analyses conducted by the Münster research team revealed low fucose concentrations in the patient’s blood, red blood cells, and cerebrospinal fluid, alongside decreased fucosylation of various proteins. During fucosylation, fucose building blocks are attached to proteins and other molecules, a process important for numerous biological processes, particularly in the nervous system. The findings indicate that disrupted fucose supply and fucosylation could play a role in the disease.
Extraction, Clinical Outlook, and Future Research
Extraction of L-Fucose typically occurs naturally from brown algae, requiring high standards of quality and availability for medical utilization. Researchers emphasize that addressing the newly identified fucose deficiency could soon become an essential component alongside ketogenic dietary management for individuals affected by GLUT1 deficiency syndrome.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.